Technical Analysis for NERV - Minerva Neurosciences, Inc

Grade Last Price % Change Price Change
F 2.25 -5.46% -0.13
NERV closed down 5.46 percent on Thursday, May 6, 2021, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: May 12
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical NERV trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup -5.46%
Lower Bollinger Band Touch Weakness -5.46%
Older End-of-Day Signals for NERV ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below Previous Day's Low about 16 hours ago
Down 5% about 17 hours ago
Possible Inside Day about 17 hours ago
60 Minute Opening Range Breakdown about 17 hours ago
Fell Below Lower Bollinger Band about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Minerva Neurosciences, Inc Description

Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Neuroscience Psychoactive Drugs Schizophrenia Parkinson's Disease Major Depressive Disorder Depressive Disorder Neurochemistry Treatment Of Parkinson's Disease Ketones Central Nervous System Disease Central Nervous System Diseases Treatment Of Major Depressive Disorder Antidepressants Insomnia Janssen Pharmaceutica Investigational New Drug Treatment Of Central Nervous System Diseases Cyren Dopamine

Is NERV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 15.215
52 Week Low 1.81
Average Volume 302,543
200-Day Moving Average 3.11
50-Day Moving Average 2.79
20-Day Moving Average 2.46
10-Day Moving Average 2.43
Average True Range 0.14
ADX 35.37
+DI 9.68
-DI 26.58
Chandelier Exit (Long, 3 ATRs ) 2.40
Chandelier Exit (Short, 3 ATRs ) 2.67
Upper Bollinger Band 2.64
Lower Bollinger Band 2.28
Percent B (%b) -0.08
BandWidth 14.69
MACD Line -0.13
MACD Signal Line -0.13
MACD Histogram -0.0001
Fundamentals Value
Market Cap 96.02 Million
Num Shares 42.7 Million
EPS -1.38
Price-to-Earnings (P/E) Ratio -1.64
Price-to-Sales 2.82
Price-to-Book 2.13
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.42
Resistance 3 (R3) 2.43 2.39 2.39
Resistance 2 (R2) 2.39 2.35 2.38 2.38
Resistance 1 (R1) 2.32 2.32 2.30 2.31 2.37
Pivot Point 2.28 2.28 2.27 2.27 2.28
Support 1 (S1) 2.21 2.24 2.19 2.20 2.13
Support 2 (S2) 2.17 2.21 2.16 2.12
Support 3 (S3) 2.10 2.17 2.11
Support 4 (S4) 2.09